Literature DB >> 8396512

The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII).

A al-Aqeel1, P Ozand, S Sobki, W Sewairi, S Marx.   

Abstract

OBJECTIVE: Some patients with rickets are resistant to vitamin D and its analogues; we therefore assessed whether or not normal mineralization could be achieved in the absence of an intact 1,25(OH)2D3 receptor-effector system, by the use of intravenous high dose calcium infusion, followed by high dose oral calcium.
DESIGN: We studied two patients with vitamin D dependent rickets type II and with absent responses to either high dose calcitriol or to oral calcium alone. Daily infusions equivalent to up to 1.4 g elemental calcium supplemented with oral phosphate were given for a period of 3.5 months for the elder sister and 2 months in the younger brother. Both patients were then treated by weekly calcium infusions for 5 months, followed by maintenance on oral calcium equivalent to up to 6 g elemental calcium per day. PATIENTS: Two siblings of consanguineous parents, a girl aged 28 months and a boy aged 10 months with vitamin D dependent rickets type II. MEASUREMENTS: Measurements of serum and urine calcium, phosphate and serum alkaline phosphatase were obtained before, during and after the calcium infusions. Twenty-four-hour urinary minerals, electrolytes, creatinine clearance, serum PTH and vitamin D metabolites were measured prior to calcium infusion, then repeated at 2-monthly intervals. Glomerular filtration rate, kidney ultrasound and CT scan were done at 6-monthly intervals. A scalp biopsy was done at the end of i.v. calcium treatment.
RESULTS: The daily infusions of calcium supplemented with oral phosphate resulted in biochemical responses with normalization of calcium and phosphate in 3-5 days, and of alkaline phosphatase and PTH in 1.5-2 months. Radiological evidence of healing was seen in 42 days. A total of 3.5 months of daily calcium infusion in the elder sister and 2 months in the younger brother resulted in complete healing biochemically and radiologically, with improvement in height. The patients are under current follow-up, with no evidence of nephrocalcinosis or deterioration of glomerular filtration rate.
CONCLUSIONS: (a) The use of intravenous high dose calcium infusions followed by high dose oral calcium is an effective method of treatment of vitamin D dependent rickets type II. (b) The treatment was more effective since it was started early in the course of the disease and led to early healing and better growth with prevention of bone deformities. (c) Early treatment may also lead to improvement in alopecia, the mechanism for which needs to be elucidated. ABBREVIATIONS: 1,25(OH)2D3, 1,25-dihydroxyvitamin D3 (calcitriol); 24-OHase, 25-(OH)D(3),24-hydroxylase; 1 alpha-(OH)D3, 1 alpha-hydroxyvitamin D3; 25(OH)D3, 25-hydroxyvitamin D3; 1 alpha-OHase, 1 alpha-hydroxylase; PTH, parathyroid hormone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396512     DOI: 10.1111/j.1365-2265.1993.tb01779.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

Review 1.  New developments in our understanding of vitamin metabolism, action and treatment.

Authors:  Sylvia Christakos; Shanshan Li; Jessica De La Cruz; Daniel D Bikle
Journal:  Metabolism       Date:  2019-06-19       Impact factor: 8.694

Review 2.  Functions of vitamin D in bone.

Authors:  D Goltzman
Journal:  Histochem Cell Biol       Date:  2018-02-12       Impact factor: 4.304

Review 3.  Vitamin D and bone.

Authors:  Daniel D Bikle
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

4.  Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness.

Authors:  P J Malloy; T R Eccleshall; C Gross; L Van Maldergem; R Bouillon; D Feldman
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

Review 5.  Vitamin D metabolism, functions and needs: from science to health claims.

Authors:  S Battault; S J Whiting; S L Peltier; S Sadrin; G Gerber; J M Maixent
Journal:  Eur J Nutr       Date:  2012-08-12       Impact factor: 5.614

6.  The Effectiveness of Cinacalcet as an Adjunctive Therapy for Hereditary 1,25 Dihydroxyvitamin D3-Resistant Rickets.

Authors:  Ayşehan Akıncı; İsmail Dündar; Meltem Kıvılcım
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-10-31

Review 7.  Genetic Causes of Rickets.

Authors:  Sezer Acar; Korcan Demir; Yufei Shi
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.